Attenuation of Glycoprotein and Hydroxyproline Levels in Sodium Valproate-Induced Brain Damage with Moringa Hydroalcoholic Extracts
Abstract
Objective: Valproic acid (VPA) and its salts are psychotropic medications that are widely used to treat neurological diseases, such as epilepsy, migraine, and neuropathic pain, as well as psychiatric disorders, such as schizophrenia, addiction, and bipolar mood disorder. Moringa extract contains antioxidant, antimicrobial, antidiabetic, cardioprotective, and anti-inflammatory compounds that may support human health.
Materials and Methods: This study aimed to investigate the possible protective effects of Moringa hydroalcoholic extract (MOL) against sodium valproate (SVP)-induced damage to brain glycoproteins and hydroxyproline. Female rats (Sprague Dawley) were randomly assigned to the following four groups: control, MOL, SVP, and SVP + MOL. SVP and MOL were administered at doses of 500 and 300 mg/kg body weight, respectively, for 15 days. Rats were sacrificed on day 16. The collection and subsequent homogenisation of brain tissue was conducted using a physiological saline solution at a ratio of 10% (weight/volume). The levels of sialic acid, hexose, hexosamine, fucose, and hydroxyproline were determined in the brain tissue.
Results: Statistical analysis revealed a significant increase in glycoprotein and hydroxyproline levels in the brain tissue of rats treated with SVP. The administration of a hydroalcoholic extract of MOL to rats treated with SVP resulted in the recovery of these alterations, thus preventing or reducing brain damage.
Conclusion: The hydroalcoholic extract of Moringa exerts an attenuating effect on brain damage associated with increased glycoprotein and hydroxyproline levels caused by SVP.
Keywords
References
- Rahman M, Awosika AO, Nguyen H. Valproic acid, Treasure Island (FL): StatPearls Publishing, [https://www.ncbi.nlm.nih.gov/books/NBK559112/(accessed](https://www.ncbi.nlm.nih.gov/books/NBK559112/(accessed) on 18 October 2025). google scholar
- Schwartz TL, Massa JL, Gupta S, Al-Samarrai S, Devitt P, Masand PS. Divalproex sodium versus valproic acid in hospital treatment of psychotic disorders. Prim Care Companion J Clin Psychiatry, 2000;2(2):45-48.google scholar
- Bairy LK, Madhyastha S. Advancements in valproate therapy for seizures, migraines, and bipolar disorders. Med Princ Pract. 2025;34:301-315. google scholar
- Bischof MC, Stadelmann MI, Janett S, et al. Valproic acid-associated acute pancreatitis: Systematic literature review. J Clin Med. 2023;12(18):6044. doi:10.3390/jcm12186044 google scholar
- Bayrak BB, Sancar S, Cakmak NH, Bolkent S, Yanardag R. Ameliorative effects of edaravone against valproic acid-induced kidney damage. J Mol Histol. 2025;56(1):4. doi:10.1007/s10735-024-10291-5 google scholar
- Kadam R, Palkar M, Pingili RB. Mechanisms involved in the valproic acid- induced hepatotoxicity: A comprehensive review. Toxicol Mech Method. 2025;35(6):565-580. google scholar
- Magaji UF, Koroglu P, Coremen M, Bulan OK, Sacan O, Yanardag R. Effects of Moringa oleifera extract on biochemical and histological parameters of sodium valproate induced lungs damage. J Mol Histol. 2025;56(1):56. doi:10.1007/ s10735-024-10345-8 google scholar
- Terim Kapakin KA, Bolat İ, İskender H, et al. Protective effects of curcumin against valproic acid induced brain kidney and liver damage in rats. Drug Chem Toxicol. 2025;48(3):644-659. google scholar
Details
Primary Language
English
Subjects
Toxicology
Journal Section
Research Article
Authors
Mehraj Babayev
0009-0005-7864-5807
Türkiye
Umar Faruk Magaji
0000-0002-4009-481X
Türkiye
Özlem Saçan
0000-0001-6503-4613
Türkiye
Refiye Yanardağ
0000-0003-4185-4363
Türkiye
Publication Date
June 12, 2026
Submission Date
December 31, 2025
Acceptance Date
February 17, 2026
Published in Issue
Year 2026 Volume: 85 Number: 2